Skip to content

LifeVest Post-CABG Registry

Post-market Release Registry of Wearable Defibrillator Use in Patients With Ventricular Dysfunction Following CABG Surgery

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01448005
Enrollment
69
Registered
2011-10-06
Start date
2011-02-28
Completion date
2014-10-31
Last updated
2017-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Ischemia, Sudden Cardiac Death, Ventricular Dysfunction, Ventricular Fibrillation, Ventricular Tachycardia

Keywords

Coronary Artery Bypass Grafting, Resuscitation, Sudden Cardiac Death, Ventricular Dysfunction

Brief summary

This is a multi-center prospective registry of patients with an ejection fraction (EF) ≤ 35% following coronary artery bypass graft (CABG) surgery in order to test the hypothesis that wearable defibrillators (WD) will decrease overall mortality after discharge by decreasing arrhythmic death in this select population with high risk for sudden cardiac death (SCD). This is a pilot project to determine the feasibility of a larger-scale study.

Interventions

A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.

Sponsors

Zoll Medical Corporation
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who have undergone CABG surgery during current hospitalization * Patients who have an ejection fraction ≤ 35% following the surgery. * Patients who have dilated cardiomyopathy or prior myocardial infarction. * Patients who are prescribed a wearable defibrillator following surgery. * Patient who are at least 18 years old.

Exclusion criteria

* Patients who have an active ICD. * Patients who have an active unipolar pacemaker. * Patients having a chest circumference over 56 inches or under 26 inches. * Patients who are unable to consent or unwilling to wear the WCD after discharge or who do not agree to be contacted at 90 days. * Patients with a mental, visual, physical or auditory deficit that could impair their ability to properly interact with a wearable defibrillator. * Patients participating in another clinical study with mortality as the primary endpoint. * Patients unable to use a wearable defibrillator due to physical conditions (bandages preventing electrode contact, physical deformities preventing electrode contact, dextrocardia, etc.). * Patients who have decided to forgo resuscitation.

Design outcomes

Primary

MeasureTime frame
number of patients who experience sudden cardiac deaththree months

Secondary

MeasureTime frame
number of patients who experience inappropriate shocksthree months
hours per day of wearable defibrillator usethree months
number of patients who experience sudden cardiac arrestthree months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026